Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function Seaport Therapeutics a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a…
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cataract surgery.…
Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that the…
Polares Medical Raises $50 Million Series C to Advance U.S. Expansion of MRace Following Strong Clinical Results Polares Medical SA a clinical-stage structural heart company developing the MRace Posterior Leaflet Replacement (PLR) system for mitral regurgitation (MR), today announced the closing of…
Mobile Heartbeat’s Banyan Platform Connects Health System Staff Across the Enterprise Through Microsoft Teams Mobile Heartbeat, a proven leader in enterprise clinical communication and collaboration (CC&C), is spotlighting how its Banyan platform’s Microsoft Teams integration is helping healthcare organizations extend secure, real-time…
Humana Introduces New Value-Based Cardiology Care Partnerships for Medicare Advantage Members Humana Inc. a leading U.S. healthcare company, today announced new partnerships to improve heart health for eligible Medicare Advantage members through value-based care. Building on Humana’s existing cardiac care partnership…
STAAR Surgical Releases Update in New Shareholder Letter STAAR Surgical Company the global leader in phakic intraocular lenses (IOLs) and maker of the EVO family of Implantable Collamer® Lenses (EVO ICL™), issued a Shareholder Letter on March 3 following market…
AN2 Therapeutics, Inc. Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics derived from its proprietary boron chemistry platform, today announced plans…
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and…
Delcath Systems Reports Publication of CHOPIN Clinical Trial Findings in The Lancet Oncology Delcath Systems, Inc. an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full results from the…
ARPA-H Awards Up to $15 Million to Seaport Therapeutics and Monash Institute to Advance First Oral Therapy Targeting Gut Lymphatic Dysfunction Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative medicines, has announced that it has been awarded up…
EU Regulatory Reforms and Global Healthcare Innovation to Be Central Focus at DIA Europe 2026 DIA, a global non-profit association of life sciences professionals, has announced that DIA Europe 2026 will convene leading voices from across Europe and around the…